Abstract:Aims/Hypothesis: Heterozygous inactivating mutations in the glucokinase (GCK) gene are known to cause maturity-onset diabetes of the young (GCK-MODY). We identified a novel variant of uncertain significance (VUS) GCK mutation (c.77A>T, p.Q26L) in two family members presenting markedly different severities of diabetic phenotypes. This study aimed to elucidate the potential diabetogenic effect of GCK-Q26L and to explore the mono- and poly-genetic background attributing to different diabetes phenotypes. Methods: Whole- exome sequencing (WES) and genetic analyses, including polygenic risk score (PRS) assessments, were performed in three members of a family with early-onset diabetes. To elucidate the impact of the GCK-Q26L mutation on glucose homeostasis, a global knock-in mouse model harboring this mutation in both heterozygous and homozygous states was generated. Insulin content and insulin secretion response to glucose and potassium were evaluated in isolated islets. Furthermore, the effects of dorzagliatin (a glucokinase activator, GKA) and liraglutide (a glucagon like peptide 1 receptor agonist, GLP-1RA) on glucose tolerance and insulin secretion were assessed in GCK-Q26L mutant mice. Results: The proband, who inherited the GCK-Q26L mutation from her father (presenting with non-progressive, mildly elevated blood glucose), exhibited severe diabetic phenotypes including polydipsia, polyuria, polyphagia, weight loss, and ketosis, accompanied by significant dyslipidemia. Genetic analyses revealed that the proband's severe phenotypes and metabolic profiles were associated with a high polygenic risk score (PRS) for insulin resistance that was inherited from her mother. Global heterozygous GCK-Q26L knock-in mice showed a mild increased fasting blood glucose, impaired glucose tolerance (IGT), and decreased serum insulin. Homozygous GCK-Q26L mice presented more severe phenotypes compared to their heterozygous counterparts, confirming the diabetogenic nature of the GCK-Q26Lmutation. Further analyses indicated that GCK-Q26L did not affect insulin sensitivity and islet insulin content. However, GCK-Q26L blunted islet responsiveness to different glucose concentrations and markedly impaired glucose-stimulated insulin secretion (GSIS) without affecting potassium chloride-stimulated insulin secretion (KSIS) and glucose inhibitory effects on glucagon secretion. Both GKA and GLP-1RA enhanced insulin secretion and improved glucose tolerance in mutant mice. Conclusions/Interpretation: This study demonstrates that GCK-Q26L is a GCK-MODY causing mutation. The interplay of GCK-Q26L with a high PRS for insulin resistance contributes to severe diabetic phenotypes. The findings not only expends the list of GCK-MODY causing mutations originally classified as VUS mutations, but also provides insights into interactions of GCK-MODY with polygenic risks of type 2 diabetes, highlighting the importance of considering polygenic backgrounds in the assessment and management of monogenic diabetes. Keywords: monogenic diabetes, glucokinase, GCK-MODY, insulin resistance, polygenic risk score (PRS)

A family harboring an MLKL loss of function variant implicates impaired necroptosis in diabetes

A common human MLKL polymorphism confers resistance to negative regulation by phosphorylation

A Novel KLF11 Variant in a Family with Maturity-Onset Diabetes of the Young

Unraveling the genetic basis of MODY: insights from next-generation sequencing

Dominant-negative Suppression of HNF-1α Results in Mitochondrial Dysfunction, INS-1 Cell Apoptosis, and Increased Sensitivity to Ceramide-, but Not to High Glucose-induced Cell Death

A Korean Family Presenting with Renal Cysts and Maturity-Onset Diabetes of the Young Caused by a Novel In-Frame Deletion of HNF1B

Screening and Functional Analysis of Mutations in NEUROD1 Gene in Pedigrees of Maturity-Onset Diabetes of the Young

Genotype-phenotype discrepancy among family members carrying a novel glucokinase mutation: insights into the interplay of GCK-MODY and insulin resistance

A Novel KLF11 c.793G>A (p.Glu265Lys) Variant Identified in a Chinese Family with Controversial Association with MODY7

Functional Characterization of a Novel Heterozygous Mutation in the Glucokinase Gene That Causes MODY2 in Chinese Pedigrees

A novel nonsense mutation c.747C>G in the NEUROD1 gene detected within a Chinese family affected by maturity‐onset diabetes of the young type 6

Clinical and Functional Characterization of a Novel KCNJ11 (c.101g > A, P.r34h) Mutation Associated with Maturity-Onset Diabetes Mellitus of the Young Type 13

Non-Necroptotic Roles of MLKL in Diet-Induced Obesity, Liver Pathology, and Insulin Sensitivity: Insights from a High Fat, High Fructose, High Cholesterol Diet Mouse Model

Assessment of pathogenicity and functional characterization of APPL1 gene mutations in diabetic patients

1466-P: Screening and Functional Analysis of Mutations and Variations in NEUROD1 Gene in Pedigrees of Maturity-Onset Diabetes of the Young

Phenotypic and Genetic Heterogeneity in a Thai Glucokinase MODY Family Reveals the Complexity of Young-Onset Diabetes

Co-inheritance of Rare Variants of Maturity-Onset Diabetes of the Young (MODY): A Case Report and Review of the Literature

MLKL-mediated necroptosis is a target for cardiac protection in mouse models of type-1 diabetes

The MODY-associated L114P mutation increases islet glucagon secretion and limits insulin secretion resulting in transient neonatal diabetes and glucose dyshomeostasis in adults

Genetic Modifiers of the Age at Diagnosis of Diabetes (MODY3) in Carriers of Hepatocyte Nuclear Factor-1Alpha Mutations Map to Chromosomes 5p15, 9q22, and 14Q24.

Studies of Genetic Variability of the Hepatocyte Nuclear Factor-1Α Gene in an Indian Maturity-Onset Diabetes of the Young Family.